Selective androgen receptor modulator (SARM)

Andarine (S-4)

Andarine (S-4) had a half-life of 2.6 to 5.3 hours in rats, and the app lists 4 hours; no human pharmacokinetic study was identified.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Andarine (S-4) after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.

Drawn from the half-life in the app's model, ~4 h. The model's figures

Kearbey and colleagues describe S-4, the compound sold as andarine, as "a non-steroidal selective androgen receptor modulator demonstrating tissue-selective androgenic and anabolic effects".1 The app lists it in the SARM category with an oral route and a typical dose of 25–50 mg/day. A 2024 review by Leciejewska and colleagues in the European Journal of Clinical Pharmacology states that "none has been approved by the Food and Drug Administration (FDA) or European Medicines Agency for pharmacotherapy", referring to SARM agonists as a group.2 The same review states that "preclinical studies on the andarine (S-4) compound, which is also available for sale online, were suspended and did not advance to phase I of clinical trials".2 Thevis and colleagues, in Drug Testing and Analysis in 2009, reported S-4 at approximately 150 mg/mL in oily liquids sold online and declared as green tea extracts and face moisturizer.3 They write that misuse of SARMs without clinical approval "was proved for the first time by the detection of the drug candidate Andarine".3

The app grades the evidence for andarine as moderate, but the studies described below were done in rats, and no controlled trial of andarine in people was identified in PubMed or ClinicalTrials.gov.

2

How it works

Gao and colleagues, Endocrinology, 2005, studied S-4 in castrated male rats and report that "S-4 does not interact with the ER and cannot be aromatized", and the authors reason that its bone effects are mediated only by direct action on the androgen receptor (AR).4 In that study the authors write that "S-4 demonstrates weak androgenic activity in the prostate at doses capable of maximally promoting anabolic activity".4 In castrated rats, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) had increased dramatically by 20 weeks after castration; S-4 lowered them in a dose-dependent manner, restoring LH to intact levels at 10 mg/kg but not fully returning FSH to the intact level, which the authors read as agonist activity in the pituitary.4 The authors add that this "corroborates our prior findings in shorter-term (i.e. 9 d) studies that S-4 has minimal effects on endogenous testosterone production".4 The app flags andarine as suppressive; the rat data above come from castrated animals, and no measurement of testosterone in people taking andarine was identified. Leciejewska and colleagues suggest on structural grounds that "the presence of selected toxicophores, such as Ar–NO2 in andarine, may be associated with higher toxicity of this compound".2

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 h
Bioavailability
95%
Typical dose
25–50 mg/day
Route
Oral
Time to peak
~1.5 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics6 rows
ParameterApp's figureReported in the sources
Half-life~4 hIn male Sprague–Dawley rats, 2.6 to 5.3 h over the doses tested; intravenous half-lives of 154, 182, 223 and 316 min at 0.5, 1, 10 and 30 mg/kg; oral half-lives of 203, 173 and 266 min at 1, 10 and 30 mg/kg; no human figure identified1
Bioavailability95%In rats by gavage, complete at 1 and 10 mg/kg and 57% at 30 mg/kg; the authors predicted a bioavailability above 95% from a hepatic extraction ratio below 0.05; no human figure identified1
Time to peak~1.5 hIn rats, time to maximal plasma concentration of 48, 84 and 336 min after oral doses of 1, 10 and 30 mg/kg; no human figure identified1
Volume of distributionNot listedAbout 0.448 l/kg in rats1
Clearance and excretionNot listedIn rats, intravenous clearances of 1.0 to 2.1 ml/min/kg that varied with dose; less than 0.15% of the drug excreted unchanged in urine, which was collected from the high-dose group1
Urinary metabolitesNot listedGlucuronic acid conjugates of the active drug and of its monohydroxylated and/or deacetylated product are among the urinary metabolites characterized for doping control; the record does not state the species5

The app's figures of about 4 hours, 95% and about 1.5 hours fall within the ranges of the rat figures above, which vary with dose, and the sources report no human half-life, bioavailability or peak time for andarine. The authors of the rat paper compare S-4 with bicalutamide and write that S-4 "is cleared much more rapidly with an average half-life of about 4 h".1 The app lists a one-compartment model; the sources retrieved do not state why that model was chosen.

4

Human studies

No controlled trial of andarine in people was identified in PubMed or ClinicalTrials.gov, and the Leciejewska review states that preclinical work on andarine "did not advance to phase I of clinical trials".2 The table below therefore lists the three rat studies retrieved and one human case summarized in a review; the first three rows are animals, not people.

Table 4.1Human studies4 rows
Study and yearDesignPeopleDose and lengthMain result
Kearbey and colleagues, Xenobiotica 20041Pharmacokinetic study with intravenous and oral groups; supported in part by NIH and GTx, Inc.135 male Sprague–Dawley rats, about 250 g (animals, not people)1Intravenous 0.5, 1, 10, 30 mg/kg; oral 1, 10, 30 mg/kg1Half-life 2.6 to 5.3 h; oral bioavailability complete at lower doses and 57% at 30 mg/kg1
Gao and colleagues, Endocrinology 20054Efficacy study in castrated rats against vehicle and dihydrotestosterone (DHT); NIDDK grant4Male Sprague Dawley rats castrated at 12 weeks of age, groups of seven to eight animals (animals, not people)4S-4 3 or 10 mg/kg by daily subcutaneous injection for 8 weeks, started 12 weeks after castration4Levator ani weight restored; prostate and seminal vesicle at 16 and 17% of control at 3 mg/kg; soleus mass change not significant4
Kearbey and colleagues, Pharmaceutical Research 20096Bone study in gonadectomized or sham-operated aged female rats; funding not stated in the retrieved record6Aged female rats; number not stated in the retrieved record (animals, not people)6Daily from day 90 to day 210; dose and route not stated in the retrieved record6Whole-body and lumbar (L5-L6) bone mineral density restored to intact-control level; femoral midshaft cortical bone quality increased6
Case in the Leciejewska review, Eur J Clin Pharmacol 2024 (case attributed to Sotorník and colleagues)2Case report summarized in a review; the review reports no competing interests2One person; the row lists metabolic syndrome, dyslipidemia and liver steatosis and insulin therapy2Andarine 25 mg twice daily with RAD-140 5 mg twice daily; onset at 9 weeks2Polydipsia, polyuria, blurred vision, weight loss, hyperglycemia, hypertension; ibutamoren also listed2

Deeper analysis: the rat pharmacokinetic study (Kearbey, 2004)

Kearbey and colleagues gave 35 male Sprague–Dawley rats intravenous doses of 0.5, 1, 10 or 30 mg/kg or oral doses of 1, 10 or 30 mg/kg by gavage, with five animals per group, and measured plasma concentrations by high-performance liquid chromatography or HPLC with mass spectrometry.1 Clearance was close to constant at 0.5, 1 and 10 mg/kg (1.92, 2.12 and 1.52 ml/min/kg) and lower at 30 mg/kg (1.00 ml/min/kg), and the authors write that "saturation of the drug-metabolizing enzymes might be occurring at this higher dose".1 At 30 mg/kg by mouth the time to peak lengthened and bioavailability fell to 57%, which the authors attribute as "most likely due to the poor aqueous solubility of the compound (about 80 μg ml−1)".1 They also write that "decreased p.o. bioavailability at higher doses may serve as a protective mechanism given the potential for abuse of an anabolic drug such as S-4".1 The authors state that, in urine collected from the high-dose group, less than 0.15% of the drug was excreted unchanged, "indicating that renal clearance of S-4 was negligible".1 The paper has no stated limitations section in the text read; the authors note that "forthcoming data from the present authors' laboratory will provide needed information about the hepatic metabolism and pharmacokinetics of S-4 in this and other species".1 The authors conclude that the "pharmacokinetics and oral bioavailability of S-4 indicate that it is an excellent candidate for clinical development", and refer to forthcoming reports on "pharmacokinetics and metabolism in dogs and humans".1 The study was supported in part by NIH grants and by GTx, Inc., and the retrieved text has no competing-interest statement.1

Deeper analysis: the castrated-rat study (Gao, 2005)

Gao and colleagues castrated 12-week-old male Sprague Dawley rats, waited 12 weeks, then gave S-4 3 or 10 mg/kg, DHT 3 mg/kg or vehicle for 8 weeks by daily subcutaneous injection, with groups of seven to eight animals; the injection route differs from the oral route the app lists.4 Measured outcomes were muscle strength and weights of the soleus and levator ani muscles, prostate and seminal vesicle, body composition and bone density by dual x-ray absorptiometry, and serum IGF-I, osteocalcin, LH and FSH.4 The authors' summary says S-4 at 3 and 10 mg/kg "restored soleus muscle mass and strength and levator ani muscle mass to that seen in intact animals", while the results text says S-4 and DHT "tended to increase soleus muscle mass in ORX animals, but the change was not significant due to the larger variability of the data".4 DHT at 3 mg/kg "significantly increased the prostate and seminal vesicle weights by more than 2-fold, compared with the intact animals", whereas S-4 at 3 mg/kg returned them to 16 and 17% of control levels; at 10 mg/kg the authors report "stronger androgenic effects in the prostate and seminal vesicle" than at 3 mg/kg.4 S-4 restored lean mass, increasing it by 15 g in 8 weeks, but "did not decrease the fat mass in ORX animals", unlike DHT, and S-4 produced "a significantly larger increase in total body bone mineral density than DHT".4 S-4 did not change IGF-I ("S-4 (3 or 10 mg/kg) treatment did not affect IGF-I levels"), restored LH to intact levels at 10 mg/kg, and at that dose "did not fully return the FSH level to the intact control level".4 In the discussion the authors write that "S-4 treatment tends to increase IGF-I expression in ORX animals", while DHT significantly decreased it.4 The authors describe the mechanism behind the fat-mass and bone differences as a hypothesis, writing that "more detailed gene expression experiments need to be conducted to confirm this hypothesis".4 The paper is a rat study with no human data, and the retrieved text names only the NIDDK grant as support and has no competing-interest statement; the S-4 used "was synthesized by Dr. Duane Miller's research group at the University of Tennessee", and Miller is a listed author.4

Deeper analysis: the osteopenic female rat study (Kearbey, 2009)

Kearbey and colleagues, from the College of Pharmacy, The Ohio State University, gonadectomized or sham-operated aged female rats on day 1, started dosing on day 90 and continued daily until day 210.6 They report that S-4 "restored whole body and lumbar vertebrae (L5-L6) BMD to the level of intact controls" and that cortical bone quality increased at the femoral midshaft.6 Their conclusion calls the recovery "partial/complete", and the retrieved record gives no dose, route, group size, funding statement or limitations.6 The record lists a contact address at gtxinc.com for Kearbey and gives the publication type as Research Support, Non-U.S. Gov't; the same group's 2004 rat pharmacokinetic study was supported in part by GTx, Inc., and no funding or competing-interest statement is in the retrieved record.6,1

Deeper analysis: the case review (Leciejewska, 2024)

Leciejewska and colleagues searched PubMed for articles published from 16 September 2022 to 2 October 2023 and included 20 records, and the review says that 20 reports of adverse events since 2020, most described as drug-induced liver injury associated with the use of SARM agonists, have been published.2 Its table lists one case involving andarine, attributed to Sotorník and colleagues: andarine 25 mg twice daily and RAD-140 5 mg twice daily, with polydipsia, polyuria, blurred vision and weight loss, hyperglycemia and hypertension, onset at 9 weeks, and ibutamoren listed as a co-used product.2 The review states that in the case reports "the exact dose of SARMs used by the subjects was not specified in most cases" and that "no laboratory analysis was performed to confirm the purity and content of the substances".2 The authors conclude that "the lack of quality control of consumed supplements makes it very difficult to assess the direct impact of SARMs on the liver and their potential hepatotoxic effects".2 The review's conflict statement reads "The authors declare no competing interests", and its funding statement names the National Science Centre, project number 2019/35/N/NZ7/00738.2

5

Doses reported in studies and on labels

No label for andarine was identified in a DailyMed search, so no label dose is reported here. The upper end of the app's 25–50 mg/day range equals the daily total of the one human case in the review (25 mg twice daily), and no trial or label source for the app's range was identified.2

Table 5.1Doses reported in studies and on labels4 rows
Setting and sourceDose and routeDurationn and comparator
Rat pharmacokinetics, Kearbey 200410.5, 1, 10, 30 mg/kg intravenous; 1, 10, 30 mg/kg oral by gavagePlasma concentration-time profilesFive rats per dose group; no comparator group
Castrated rats, Gao 200543 or 10 mg/kg daily by subcutaneous injection8 weeks, started 12 weeks after castrationSeven to eight rats per group; vehicle (castrated and intact) and DHT 3 mg/kg
Osteopenic female rats, Kearbey 20096Not stated in the retrieved recordDaily from day 90 to day 210Gonadectomized and sham-operated groups; n not stated
One human case in a review, Leciejewska 20242Andarine 25 mg twice daily, with RAD-140 5 mg twice daily; route not given in the rowOnset at 9 weeksOne person; no comparator; the review states no laboratory analysis was performed to confirm the purity and content of the substances, apart from one study that found the content of LGD-4033 and RAD-140, and does not say whether that is this case
6

Side effects reported

No controlled trial of andarine in people was identified in the searches, so no trial adverse event rates are reported here. The one human case in the Leciejewska review lists polydipsia, polyuria, blurred vision, weight loss, hyperglycemia and hypertension in a person who also used RAD-140 and ibutamoren, and the same row lists metabolic syndrome, dyslipidemia and liver steatosis from 3 years earlier and insulin therapy, so the review's row cannot attribute these to andarine alone.2 The review also tabulated reports in the US FDA's CFSAN Adverse Event Reporting System (CAERS) under the keywords "andarine" and "S-4".2 Three entries name andarine products: a 27-year-old male with dizziness and presyncope in 2017 (other serious or important medical event), a 26-year-old male with acute hepatic failure in 2018 (hospitalization; the review's ostarine and ligandrol rows list the same date, age, sex and term under VIRILITECH product names), and a report of cardiac death with age and sex not reported in 2019 (death).2 These are spontaneous reports, and the review's table gives product names and reported terms without laboratory confirmation of what the products contained.2 Across all the keywords searched, the review says the reports "not only included cases of liver injury but also blindness or a visual impairment, cerebrovascular accidents, paresthesia, abnormal hormone levels, testicular disorders, gynecomastia, increased blood prolactin, sexual dysfunction, altered mood, and a single fatal case of cardiac death", and these are not specific to andarine.2 The review describes an FDA warning letter on body-building products containing SARMs, "informing about the potential increase in the risk of heart attack or stroke and other life-threatening adverse reactions such as liver damage".2 In the rat studies, the prostate and seminal vesicle effects of S-4 were smaller than those of DHT at 3 mg/kg and larger at 10 mg/kg than at 3 mg/kg.4

7

Bloodwork and markers

The app lists Total T, Lipids and Liver Enzymes as markers to monitor for andarine. No human measurement of these markers in people taking andarine was identified. For testosterone, the rat authors report that LH and FSH had risen after castration and that S-4 lowered them toward intact levels, writing that this partial repression "corroborates our prior findings in shorter-term (i.e. 9 d) studies that S-4 has minimal effects on endogenous testosterone production".4 For liver enzymes, the Leciejewska review states for SARMs as a group that "most of the AEs associated with the intake of SARMs are drug-induced liver injuries (DILI)", and its cases are mostly for other SARMs.2 For lipids, the review states for SARMs as a group that "the effect of SARMs on lipid metabolism is an area that requires further investigation", reports changes in animal models, and says the lowering of high-density lipoprotein was confirmed in clinical trials, with results returning to baseline after treatment and covering 14 to 86 days.2

The 2026 WADA Prohibited List names andarine as an example of a SARM in S1.2, other anabolic agents, in the S1 anabolic agents class.7 The S1 class is prohibited at all times, in and out of competition, and all prohibited substances in S1 are non-Specified Substances.7 Thevis and colleagues write that "In 2008, SARMs were added to the Prohibited List established by the World Anti-Doping Agency (WADA)".3 The Leciejewska review's table of SARM detection in the WADA Anti-Doping Testing Figures 2011–2020 lists S-4 (andarine) occurrences of 1, 1, 1, 3, 1 and 2 for 2020, 2019, 2018, 2017, 2016 and 2015, and gives only totals for all SARMs for 2011 to 2014.2 On approval, the review states that no SARM agonist has been approved by the FDA or European Medicines Agency for pharmacotherapy, and Thevis and colleagues write that "no representative drug candidate has yet received full clinical approval".2,5 The review also describes FDA warnings about the health risks of body-building products containing SARMs, and no US label for andarine was identified in DailyMed.2

9

What is not known

Sources in this part

  1. 2Leciejewska et al., 2024
  • No human half-life, bioavailability, time to peak, volume of distribution or clearance for andarine was identified, and the rat figures above vary with dose.
  • No controlled human trial of andarine was identified in PubMed or ClinicalTrials.gov, so efficacy and adverse event rates in people are not reported in the sources.
  • The reason preclinical work on andarine was suspended is not stated in the review passage read.2
  • The one human case in the review involved other products, and the review states generally that no laboratory analysis was performed to confirm the purity and content of the substances, apart from one study that found the content of LGD-4033 and RAD-140.2
  • The source of the app's 25–50 mg/day range, its one-compartment model and its 8-hour duration of activity was not identified.
What is the half-life of andarine?

In rats, the half-life of S-4 was between 2.6 and 5.3 hours across the doses tested, and the app lists about 4 hours.1 No human half-life was identified in the PubMed or DailyMed searches.

What is the oral bioavailability of andarine?

In rats, S-4 was completely bioavailable by gavage at 1 and 10 mg/kg and 57% bioavailable at 30 mg/kg, and the app lists 95%.1 No human bioavailability figure was identified.

How long does andarine take to reach its peak level?

In rats, the time to maximal plasma concentration was 48, 84 and 336 minutes after oral doses of 1, 10 and 30 mg/kg, and the app lists about 1.5 hours.1

Is andarine banned by WADA?

Yes, the 2026 WADA Prohibited List names andarine as an example of a SARM under S1.2, other anabolic agents.7 The S1 class is prohibited at all times, in and out of competition.7

Is andarine FDA-approved?

The Leciejewska review states that none of the SARM agonists has been approved by the FDA or European Medicines Agency for pharmacotherapy.2 It adds that preclinical studies on andarine "were suspended and did not advance to phase I of clinical trials", and no US label for andarine was identified in DailyMed.2

Has andarine been tested in human clinical trials?

No controlled trial of andarine in people was identified in PubMed or ClinicalTrials.gov. The three rat studies retrieved share the authors Miller and Dalton, the 2005 and 2009 papers list The Ohio State University, and the 2004 study was supported in part by GTx, Inc.4,6,1

Is andarine a steroid?

The rat pharmacokinetic paper describes S-4 as a non-steroidal selective androgen receptor modulator.1 Gao and colleagues report that "S-4 does not interact with the ER and cannot be aromatized".4

What side effects have been reported with andarine?

No trial adverse event rates are reported here, because no controlled trial in people was identified. The Leciejewska review lists one case with andarine, RAD-140 and ibutamoren and polydipsia, polyuria, blurred vision, weight loss, hyperglycemia and hypertension, and three CAERS entries for andarine products (dizziness and presyncope, acute hepatic failure, cardiac death), the acute hepatic failure entry matching entries listed under ostarine and ligandrol.2

Does andarine lower testosterone?

No measurement of testosterone in people taking andarine was identified. In castrated rats, whose LH and FSH had risen after castration, S-4 lowered LH and FSH toward intact levels in a dose-dependent manner, and the authors cite prior shorter studies showing "minimal effects on endogenous testosterone production", while the app flags andarine as suppressive.4

Has andarine been detected in products sold online?

Yes, Thevis and colleagues reported S-4 at approximately 150 mg/mL in oily liquids sold online, declared as green tea extracts and face moisturizer.3 They also reported an impurity at approximately 10% of the S-4 amount.3

12

References

  1. Kearbey JD, et al. Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica 2004. PMID 15204699
  2. Leciejewska N, et al. Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases. Eur J Clin Pharmacol 2024. PMID 38059982
  3. Thevis M, et al. Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. Drug Test Anal 2009. PMID 20355219
  4. Gao W, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005. PMID 16099859
  5. Thevis M, et al. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes. Rapid Commun Mass Spectrom 2010. PMID 20623476
  6. Kearbey JD, et al. Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats. Pharm Res 2009. PMID 19728047
  7. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list